

WORLDWIDE HEALTHCARE TRUST PLC (formerly FINSBURY WORLDWIDE PHARMACEUTICAL TRUST PLC)

Interim Management Statement – 3 months to 30 June 2010 (unaudited)

Worldwide Healthcare Trust PLC invests worldwide in pharmaceutical, biotechnology and related companies in the healthcare sector with the objective of achieving a high level of capital growth.

The 3 month period ended 30 June 2010 was a challenging one for the Company due in part to mixed performance from large pharmaceutical companies such as Novartis, which performed well following positive newsflow regarding its treatment for multiple sclerosis, and Pfizer whose performance lagged due, in part, to the unexpected stoppage of an experimental osteoarthritis drug in late stage development. Over the three-month period, the Company's fully diluted net asset value per share fell by 5.6% and the share price by 7.7%, compared to a fall of 8.6% in the Company's benchmark, the DataStream World Pharmaceutical and Biotechnology Index measured in sterling terms on a total return basis.

During this period a total of 1,637,733 shares were repurchased to be held in treasury at a cost of £10.9m (including expenses). Since the period end, to 4 August 2010, no shares have been repurchased by the Company. On 27 July 2010 the Company cancelled all of the 7,877,149 shares held in treasury. There are currently no shares held in treasury. Also, during the three month period and up to 4 August 2010, a total of 686,893 new shares were issued, raising £4.2m of additional funds for the Company, as a result of holders of subscription shares exercising their subscription rights. In the period from 30 June 2010 to 4 August 2010, the Company's fully diluted net asset value per share rose by 1.3% and the share price fell by 0.3% compared to a fall of 1.1% in the Company's benchmark.

At the Company's Annual General Meeting, held on 15 July 2010, all of the resolutions were passed. These included resolutions to amend the Company's investment policy to that of a broader healthcare sector remit, a change to its benchmark and also to change the Company's name.

The Company paid an increased interim dividend of 8.5p per share (2009: 5.0p per share) on 26 July 2010.

Trust Characteristics

	30 June 2010	31 March 2010
Number of holdings	44	44
Net assets (£m)	307.5	341.9
Net yield	1.3%	0.7%
Gearing (AIC basis)	107	111
Share price (p)	639.00	701.50
NAV (p) -undiluted	715.42	771.27
NAV (p) diluted: sub shares	698.33	744.75
NAV (p) – fully diluted for sub shares and treasury shares	690.48	740.22
(Discount)/premium (undiluted)	(10.7%)	(9.0%)
(Discount)/premium(diluted – sub shares)	(8.5%)	(5.8%)
(Discount)/premium (fully diluted)	(7.5%)	(5.2%)
Subscription share price (p)	64.00	98.00

Source: Frostrow Capital LLP

10 Largest Investments

Name	% of portfolio at 30 June 2010	% of portfolio at 31 March 2010
Novartis	8.3	5.0
Johnson & Johnson	7.3	6.9
Pfizer	7.2	5.1
Merck	7.1	4.8
Roche	6.9	6.9
Bristol-Myers Squibb	5.1	4.7
Amgen	2.9	2.8
Sawai Pharmaceutical	2.6	2.1
Hospira	2.5	2.1
Genzyme	2.5	<u>2.8</u>
	52.4	43.2

Source: Frostrow Capital LLP

Sector Analysis

	% of portfolio at 30 June 2010	% of portfolio at 31 March 2010
Large capitalisation	74.8	65.8
Small capitalisation	<u>25.2</u>	<u>34.2</u>
Total	100.0	100.0

Source: Frostrow Capital LLP

Geographical Analysis

	% of portfolio at 30 June 2010	% of portfolio at 31 March 2010
North America	63.3	71.0
Europe	25.9	17.9
Israel	0.0	2.8
Far East	<u>10.8</u>	<u>8.3</u>
Total	100.0	100.0

Source: Frostrow Capital LLP

Total Return Performance

	3 Months	1 Year	3 Years	5 Years
Share price	-7.7%	+22.6%	+35.4%	+42.1%
NAV Fully diluted	-5.6%	+24.7%	+36.6%	+54.0%
Benchmark*	-8.6%	+20.4%	+22.6%	+35.1%

Source: NAV (total return; fully diluted) and Share Price (total return) Morningstar. Benchmark – Thomson Reuters

* Benchmark – Datastream World Pharmaceutical and Biotechnology Index measured in sterling terms on a total return basis.

Past performance is not a guide to future performance.

This Interim Management Statement has been prepared solely to provide information to meet the requirements of the UK Listing Authority's Disclosure and Transparency Rules.

This Interim Management Statement is available on the Company's website www.worldwidewh.com.

The Company's net asset value per share is announced daily and is available, together with the share price, on the TrustNet website at www.trustnet.com

SEDOL Codes:

Shares – 0338530

Subscription Shares – B3VMCB0

ISIN –

Shares – GB0003385308

Subscription Shares – GB00B3VMCB07

For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP

Company Secretary

6 August 2010